A new drug application for Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel 0.38% has been accepted by the FDA, the company announced.
If approved, it would be the lowest concentrated loteprednol ophthalmic corticosteroid for the treatment of postoperative inflammation and pain after ocular surgery, according to a press release.
“The sub-micron loteprednol etabonate ophthalmic gel 0.38% will offer eye care professionals and their patients a lower concentration formulation with less frequent dosing compared to currently available formulations of loteprednol,”
Uncategorized